Patent application number | Description | Published |
20120277120 | METHODS FOR GENOMIC MODIFICATION - Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, and a nuclease capable of causing a double-strand break near or within the genomic target site. | 11-01-2012 |
20140186942 | Methods for Genomic Modification - Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, and a nuclease capable of causing a double-strand break near or within the genomic target site. | 07-03-2014 |
20150184199 | METHODS FOR GENOMIC INTEGRATION - Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker. | 07-02-2015 |
Patent application number | Description | Published |
20080208026 | SYSTEMS AND METHODS FOR DETECTING HYPOGLYCEMIC EVENTS HAVING A REDUCED INCIDENCE OF FALSE ALARMS - The present invention is directed to a method of reducing false readings in a hypoglycemic detector that includes establishing a predetermined hypoglycemic threshold, a predetermined critical threshold, a predetermined rate of change in glucose concentration where the predetermined critical threshold is below the predetermined hypoglycemic threshold. A first sampling rate is then calculated based upon said predetermined hypoglycemic threshold, said predetermined critical threshold, and said predetermined rate of change in glucose concentration. | 08-28-2008 |
20100016700 | ANALYTE MEASUREMENT AND MANAGEMENT DEVICE AND ASSOCIATED METHODS - Various embodiments of a diabetes management system are provided. One exemplary system may include an analyte measurement device and a therapeutic agent delivery device. The measurement device includes a measurement unit, display, and first wireless module. The therapeutic agent delivery device has a delivery device housing, delivery mechanism disposed in the housing that delivers a dosage of the agent to the user upon actuation by the user or health care provider, and a second wireless module. The second module, automatically, without prompting from a user or any active input or action by the user, transmits a signal to the first wireless module indicative of: (a) type of therapeutic agent delivered; and (b) amount of therapeutic agent delivered to the user; or (c) type of therapeutic agent device from which the therapeutic agent was administered. Also described are diabetes management devices and methods. | 01-21-2010 |
20100324401 | DIABETES MANAGEMENT METHODS AND SYSTEMS - The present invention relates to methods and systems for monitoring the effectiveness of diabetes treatment. Methods and systems in accordance with the present invention provide information relating to variability of glucose levels and hypoglycemia and hyperglycemia. Such information is based on time-stamped blood glucose data obtained from a meter or the like and actual measurements of HbA1c levels are not required. | 12-23-2010 |
Patent application number | Description | Published |
20080318313 | Method to Prevent Graft Rejection Using TGF-Beta to Induce T Suppressor Cells - The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation. | 12-25-2008 |
20090061514 | USE OF CYTOKINES AND MITOGENS TO INHIBIT GRAFT VERSUS HOST DISEASE - A method for inducing T cell tolerance in peripheral blood mononuclear cells (PBMCs) comprising adding a suppressive composition to said cells. | 03-05-2009 |
20090075296 | METHODS AND COMPOSITIONS FOR ASSAYING REGULATORY T CELLS - Methods and compositions for determining whether a T cell is a regulatory T cell and for determining whether a population of cells includes at least one regulatory T cell or a cell with the potential to become a regulatory T cell. The invention includes methods and compositions for detecting TGF-β on the surface of a cell. The invention also provides methods and compositions for evaluating the suppressive activity of a regulatory T cell based on the presence and/or the amount of membrane-bound TGF-β. | 03-19-2009 |
20090257988 | METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY T CELLS EX VIVO - The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses. | 10-15-2009 |
20100015112 | Methods for the Induction of Professional and Cytokine-Producing Regulatory T Cells - The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity. | 01-21-2010 |
20100221209 | Use of Cytokines and Mitogens to Inhibit Pathological Immune Responses - The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders. | 09-02-2010 |
20130084269 | Methods and Compositions for Expanding and Stabilizing Natural Regulatory T Cells - The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells. | 04-04-2013 |
Patent application number | Description | Published |
20090123503 | Conditioned Cell Culture Medium Compositions and Methods of Use - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 05-14-2009 |
20120230940 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 09-13-2012 |
20130203169 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-08-2013 |
20130209398 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-15-2013 |
20130210076 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-15-2013 |
20130210725 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-15-2013 |
20130217069 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-22-2013 |
20130217129 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 08-22-2013 |
Patent application number | Description | Published |
20090175901 | IMMUNOSTIMULATORY RECOMBINANT INTRACELLULAR PATHOGEN IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing Mycobacteria major extracellular proteins and immunostimulatory molecules. | 07-09-2009 |
20100092518 | Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use - Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic. | 04-15-2010 |
20100183547 | Unmarked Recombinant Intracellular Pathogen Immunogenic Compositions Expressing High Levels of Recombinant Proteins - Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker (“unmarked”). | 07-22-2010 |
20100215679 | METHODS AND COMPOSITIONS FOR TREATING TULAREMIA - The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia. | 08-26-2010 |
20100284963 | GROWTH REGULATABLE RECOMBINANT BCG IMMUNOGENIC COMPOSITIONS - Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to, growth regulatable and growth limited recombinant intracellular pathogen immunogenic compositions. | 11-11-2010 |
20110129492 | Immunostimulatory Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use - Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing | 06-02-2011 |
20130101614 | NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS - Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases. | 04-25-2013 |
20150056242 | NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS - Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as | 02-26-2015 |
Patent application number | Description | Published |
20090109708 | RADIANCE LIGHTING SYSTEM AND METHOD - A lighting system includes a wiring system and a plurality of light source modules adapted for connection to and disconnection from the wiring system Each light source module includes at least one light source unit including a plurality of light emitting diodes, wherein each of the light emitting diodes is independently connected with the wiring system The lighting system of the invention may be modular, allowing use of a suitable number and arrangement of light source modules for illuminating a given space or surface The lighting system may be adapted for being mounted, e g, to structures such as walls, ceilings, and the like, via a mounting assembly The lighting system may be suitable for, but not limited to, shedding visible light directly or indirectly to a space or a surface | 04-30-2009 |
20090221175 | Wire Harness Interconnection and Retention Method and Apparatus - A smaller conductor having an uninsulated portion and an insulated portion is positioned adjacent a larger conductor having an insulated portion and a conductive portion within said insulated portion and the two conductors are joined by a discontinuous metal band having respective ends extending across a top portion of said insulated portion to make electrical contact with said uninsulated portion, then bending downward on one side and then upward and through said insulated portion such that a first of said ends is positioned within said insulation and in contact with said conductive portion; the metal band bending downward on a second side and then upward and through said insulated portion such that a second of said ends is positioned within said insulation and in contact with said conductive portion | 09-03-2009 |
20100091489 | Seat Light and Plaque Holder - A seat light comprising a lamp shade component having a vertical back edge and an arcuate hood and a rectangular shroud component mountable within the lamp shade and encasing a circuit board carrying a plurality of LED's wherein the positioning of the LED's and shape of the hood cooperate to direct light down toward an adjacent aisleway, while concealing the shroud and LED's from normal view. A cooperating plaque holder adapted to be illuminated by the seat light is also disclosed. | 04-15-2010 |
20100091494 | RAIL LIGHT - A stair rail light attachable between first and second vertical stair rail posts and having an elongated central housing whose interior mounts an extrusion designed to hold and position a plurality of LED carrier members wherein the housing slidably engages respective mounting plugs pivotally attached to respective stair rail posts, thereby permitting the length of the rail light to be adjusted in the field. | 04-15-2010 |
20100132192 | Wire Harness Interconnection and Retention Method and Apparatus - A smaller conductor having an uninsulated portion and an insulated portion is positioned adjacent a larger conductor having an insulated portion and a conductive portion located within the insulated portion of the larger conductor. The two conductors are joined by a discontinuous metal band having respective ends extending across a top portion of the insulated portion of the larger conductor to make electrical contact with the uninsulated portion of the smaller conductor, then bending downward on one side of the conductor pair and then upward and through the insulated portion of the larger conductor such that a first of the ends of the metal band is positioned in contact with the conductive portion of the larger conductor; the metal band bending downward on the opposite side of the conductor pair and then upward and through the insulated portion of the larger conductor such that a second of the ends of the metal band is positioned in contact with the conductive portion of the larger conductor. | 06-03-2010 |